Sermorelin: What the Evidence Actually Shows
Sermorelin is the peptide with the strangest résumé in the anti-aging catalog: it is a former FDA-approved drug. As Geref, it treated growth hormone deficiency in children until 2008, when the manufacturer discontinued it — for business reasons, not safety, a distinction FDA later put in writing. That history is why clinics can prescribe sermorelin today while most peptides on this site are research chemicals, and it is also why the marketing around it deserves a careful read: the drug was proven for children with a deficiency, and is sold to adults without one.
How sermorelin works
Sermorelin is GHRH(1-29) — the first 29 amino acids of human growth hormone-releasing hormone, the shortest fragment that retains the parent hormone's full activity. It binds GHRH receptors in the pituitary and triggers release of the body's own growth hormone. Two consequences follow. First, the downstream feedback loops stay intact: somatostatin can still shut the pulse down, which caps how high GH can go — a built-in safety margin exogenous GH injections do not have. Second, its half-life is measured in minutes, so each injection produces one brief, roughly physiological GH pulse rather than a sustained elevation.
That short action is the honest trade-off against its relatives:
| Compound | What it is | Duration | Status |
|---|---|---|---|
| Sermorelin | Unmodified GHRH(1-29) | Minutes — one pulse per dose | Formerly approved (Geref); compounded today |
| CJC-1295 (DAC) | Modified GHRH analog | Days per dose | Research chemical; FDA restricted compounding in 2023 |
| Tesamorelin | Stabilized GHRH analog | Daily dosing | FDA approved (Egrifta) for one indication |
The evidence, tier by tier
Children with growth hormone deficiency — the proven use
This is where the real data lives. Once-daily subcutaneous sermorelin accelerated growth in GH-deficient children during the first year of therapy, and that evidence carried Geref through FDA approval in the 1990s. It is solid, human, regulatory-grade evidence — for a pediatric deficiency state that adult buyers do not have.
Older adults — hormone levels, not outcomes
The study quoted by every longevity clinic: in healthy men in their sixties and seventies, GHRH(1-29) given twice daily for two weeks restored GH and IGF-I levels toward the young-adult range. What that study measured was hormone levels. It did not measure body composition, strength, skin, sleep quality or any outcome a patient would notice — and no subsequent trial has closed that gap. The widely cited casefor sermorelin in aging is an opinion review arguing it should be better than injected GH; an argument is not a result.
Side effects: what is reported
Sermorelin's tolerability record from its drug years is comparatively good — one reason it stays popular. Reported effects cluster around the injection itself and the GH axis:
- Injection-site redness, pain or swelling — the most common, noted in the pediatric trials.
- Flushing and headache — transient, shortly after dosing.
- GH-axis effects at sustained high response — water retention, joint aches, reduced insulin sensitivity; class effects of raising GH by any route.
The class-level caution also applies: raising GH and IGF-I is not a neutral act in the presence of an undiagnosed malignancy, and anyone with an active cancer should not be raising it deliberately. See our safety overview for how we grade these risks across compounds.
Dosing references
| Context | Common amount | Frequency | Basis |
|---|---|---|---|
| Clinic / community protocols | 200–500 mcg | Once nightly, before bed | Practice-derived; no adult trial |
| Geref (pediatric GHD) | Weight-based | Once daily | Approved label, children only |
Bedtime dosing is not folklore: the largest natural GH pulse occurs in early slow-wave sleep, and a short-acting GHRH dose is timed to reinforce it. The numbers themselves, though, are practice-derived — no adult dose-finding study exists for the anti-aging use.
| Vial | Water | Concentration | 200 mcg | 500 mcg | Doses (300 mcg) |
|---|---|---|---|---|---|
| 5 mg | 2.5 ml | 2,000 mcg/ml | 10 units | 25 units | 16 |
| 10 mg | 5 ml | 2,000 mcg/ml | 10 units | 25 units | 33 |
Formula: concentration = peptide (mcg) ÷ water (ml). Volume = dose ÷ concentration. One unit on a U-100 insulin syringe = 0.01 ml. Values are for laboratory reference only.
Regulatory status
- 1990s — approved as Geref for pediatric growth hormone deficiency.
- 2008–2009 — EMD Serono discontinued production and asked FDA to withdraw the approvals; withdrawal took effect in 2009.
- 2013 — FDA published a formal determination that Geref was not withdrawn for reasons of safety or effectiveness, keeping the path open for future generic applications.
That paper trail is what separates sermorelin from most of this catalog. Because it was the active ingredient of an approved drug and left the market cleanly, compounding pharmacies and telehealth clinics prescribe it widely — while compounds like BPC-157 and ipamorelin were pushed out of compounding by FDA's 2023 bulk-substances actions. For tested athletes the distinction is moot: WADA prohibits GHRH and its analogues, sermorelin included, under section S2.
Research on Sermorelin
7 records in our research database, classified by evidence type:
- HumanThe Safety and Efficacy of Growth Hormone SecretagoguesSigalos JT, Pastuszak AW · Sexual Medicine Reviews, 2018
- HumanSermorelin: a better approach to management of adult-onset growth hormone insufficiency?Walker RF · Clinical Interventions in Aging, 2006
- HumanSermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiencyPrakash A, Goa KL · BioDrugs, 1999
- HumanOnce daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapyThorner M et al. · Journal of Clinical Endocrinology & Metabolism, 1996
Sermorelin — 5 mg / 10 mg — American Peptides
Sold as lyophilized vials for research use. Given nightly microgram dosing, per-batch purity documentation matters — HPLC and mass-spec COA provided per batch.
We may earn a commission if you buy through this link (at no extra cost to you). Sold for research purposes only.
Frequently asked questions
What is sermorelin?
Sermorelin is GHRH(1-29) — the first 29 amino acids of growth hormone-releasing hormone, which carry the full biological activity of the parent hormone. It stimulates the pituitary to release its own growth hormone rather than replacing it. It was an FDA-approved drug (Geref) for pediatric growth hormone deficiency until the manufacturer discontinued it in 2008.
Does sermorelin work for anti-aging?
The honest answer: unproven. Short-term studies in older adults show it raises GH and IGF-I levels toward the young-adult range. No outcome trial has shown that this translates into better body composition, strength, sleep or longevity in healthy adults — the anti-aging case is an extrapolation from hormone levels, not a demonstrated result.
What is the difference between sermorelin and CJC-1295?
Both are GHRH analogs. Sermorelin is the unmodified 29-amino-acid fragment with a half-life measured in minutes, producing a brief GH pulse. CJC-1295 adds modifications — with DAC, a single dose elevates GH and IGF-I for days. Shorter action means sermorelin preserves the natural pulse pattern more faithfully; it also means nightly injections.
Is sermorelin legal?
Sermorelin sits in an unusual position. Because it was the active ingredient of an approved drug and FDA formally determined Geref was not withdrawn for safety or effectiveness, compounding pharmacies and telehealth clinics prescribe it widely — a different legal footing from research-only peptides like BPC-157 or ipamorelin. It is banned for tested athletes under WADA section S2.
What sermorelin dose is used in protocols?
Clinic and community protocols commonly reference 200–500 mcg injected subcutaneously once nightly, timed before bed to reinforce the natural early-sleep GH pulse. The approved pediatric dosing of Geref was weight-based and is not the source of these adult numbers — no adult dose-finding trial for anti-aging use exists.
Sources
- Thorner M et al. Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Journal of Clinical Endocrinology & Metabolism, 1996. PubMed
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs, 1999. PubMed
- Corpas E et al. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology & Metabolism, 1992. PubMed
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging, 2006. PubMed
- Liu H et al. Systematic review: the effects of growth hormone on athletic performance. Annals of Internal Medicine, 2008;148(10):747–58. PubMed
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews, 2018;6(1):45–53. PubMed
- FDA. Determination That GEREF (Sermorelin Acetate) Injection Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness. Federal Register, March 4, 2013. Federal Register
- World Anti-Doping Agency. Prohibited List 2026, section S2.2 — GHRH and its analogues. WADA Prohibited List
Related guides
- Tesamorelin: the approved GHRH analog
- CJC-1295 & Ipamorelin: DAC, dosing and blend math
- Best peptides for muscle growth: what GH research found
- Peptide reconstitution calculator